Abbott Laboratories (ABT) : Flossbach Von Storch Ag scooped up 5,261,123 additional shares in Abbott Laboratories during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 2, 2016. The investment management firm now holds a total of 9,578,118 shares of Abbott Laboratories which is valued at $363,681,140.Abbott Laboratories makes up approximately 6.02% of Flossbach Von Storch Ag’s portfolio.
Abbott Laboratories closed down -0.53 points or -1.38% at $37.97 with 1,13,99,947 shares getting traded on Friday. Post opening the session at $38.22, the shares hit an intraday low of $37.71 and an intraday high of $38.4 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
Other Hedge Funds, Including , Ntv Asset Management reduced its stake in ABT by selling 700 shares or 3.17% in the most recent quarter. The Hedge Fund company now holds 21,356 shares of ABT which is valued at $810,887. Abbott Laboratories makes up approx 0.31% of Ntv Asset Management’s portfolio.A. D. Beadell Investment Counsel reduced its stake in ABT by selling 430 shares or 1.03% in the most recent quarter. The Hedge Fund company now holds 41,403 shares of ABT which is valued at $1,825,044. Abbott Laboratories makes up approx 1.66% of A. D. Beadell Investment Counsel’s portfolio.Moreno Evelyn V boosted its stake in ABT in the latest quarter, The investment management firm added 2,855 additional shares and now holds a total of 79,780 shares of Abbott Laboratories which is valued at $3,516,702. Abbott Laboratories makes up approx 1.34% of Moreno Evelyn V’s portfolio.Watch Point Trust Co reduced its stake in ABT by selling 1,240 shares or 2.46% in the most recent quarter. The Hedge Fund company now holds 49,155 shares of ABT which is valued at $2,166,752. Abbott Laboratories makes up approx 1.90% of Watch Point Trust Co’s portfolio.Ferguson Wellman Capital Management Inc reduced its stake in ABT by selling 647 shares or 1.09% in the most recent quarter. The Hedge Fund company now holds 58,757 shares of ABT which is valued at $2,590,009. Abbott Laboratories makes up approx 0.11% of Ferguson Wellman Capital Management Inc’s portfolio.
On the company’s financial health, Abbott Laboratories reported $0.41 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Apr 20, 2016. Analyst had a consensus of $0.39. The company had revenue of $4885.00 million for the quarter, compared to analysts expectations of $4777.68 million. The company’s revenue was down -.2 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.47 EPS.
Many Wall Street Analysts have commented on Abbott Laboratories. Company shares were Reiterated by RBC Capital Mkts on Apr 11, 2016 to “Outperform”, Firm has raised the Price Target to $ 48 from a previous price target of $45 .
Abbott Laboratories (Abbott) is engaged in the discovery development manufacture and sale of a range of health care products. Abbott operates in four business segments: Established Pharmaceutical Products Diagnostic Products Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks hospitals commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary endovascular structural heart vessel closure and other medical device products.